Breaking News Instant updates and real-time market news.

ALGN

Align Technology

$217.24

3.61 (1.69%)

16:10
10/23/19
10/23
16:10
10/23/19
16:10

Align Technology sees Invisalign case shipments up 20%-22% year-over-year

Align Technology sees Q4 Invisalign case shipments in the range of 400K-407K, up approximately 20%-22% over the same period a year ago.

  • 23

    Oct

ALGN Align Technology
$217.24

3.61 (1.69%)

10/07/19
LEHM
10/07/19
NO CHANGE
Target $272
LEHM
Overweight
Barclays clear aligner survey positive for Align Technology
Barclays analyst Steve Valiquette views his clear aligner survey last week to gauge U.S. trends for Q3 as positive for Align Technology. Based on the survey, the analyst believes the U.S. volume outlook looks solid, and his Align Technology revenue growth assumptions of 21% in 2019 and 23% in 2020 are unchanged. Further, respondents indicated there was no notable Invisalign discounting program in Q3 beyond the normal volume-tier discounts, Valiquette tells investors in a research note. The analyst lowered his price target for Align Technology to $272 from $300 and keeps an Overweight rating on the shares.
10/07/19
STFL
10/07/19
NO CHANGE
Target $290
STFL
Buy
Align Technology shares oversold at current levels, says Stifel
Stifel analyst Jonathan Block, who initiated coverage of SmileDirectClub (SDC) with a Buy rating and $19 price target this morning, said in a separate note to investors that he continues to view Align Technology (ALGN) as his preferred name in the clear aligner space. While challenges, such as foreign exchange headwinds and China's macro issues, remain, EMEA has been strong for the company and he "likes what he sees so far" within his proprietary U.S. due diligence, Block tells investors. He views Align shares as oversold at current levels and expects "worst case fears" around Align's share losses to SmileDirect to ease in coming quarters, Block noted. He keeps a Buy rating on Align shares with a $290 price target.
10/17/19
STFL
10/17/19
NO CHANGE
Target $290
STFL
Buy
Align Technology survey results support positive stance, says Stifel
Stifel analyst Jonathan Block said his recent survey work on Align Technology has been favorable and supports his positive stance, with providers citing "solid" Invisalign momentum at their practices, "healthy" 2020 case volume expectations, and little incremental progress from competing traditional clear aligner offerings. His checks also detected some acknowledgement of incremental Invisalign case volume resulting from Align's increased sales force investments, noted Block, who keeps a Buy rating and $290 price target on Align shares.
10/23/19
NRCS
10/23/19
NO CHANGE
Target $299
NRCS
Buy
Northcoast analysis shows favorable utilization trends for Align's Invisalign
Northcoast analyst David Keiser says that despite a more competitive clear aligner market, his North American Invisalign doctor analysis suggests favorable utilization trends have continued. 13 additional Invisalign doctors in the analyst's sample size reached the four upper tiers of Align Technology's Invisalign Advantage Program, and he also saw a sequential increase of 85 Invisalign doctors in the Silver level of the Invisalign Advantage program. Keiser maintains a Q3 earnings per share estimate of $1.16 for Align Technology, which is 2c ahead of consensus. He reiterates a Buy rating on the shares with a $299 price target.

TODAY'S FREE FLY STORIES

PAG

Penske Automotive

$51.36

0.015 (0.03%)

17:13
11/13/19
11/13
17:13
11/13/19
17:13
Syndicate
Breaking Syndicate news story on Penske Automotive »

Penske Automotive files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

LLY

Eli Lilly

$112.85

-0.31 (-0.27%)

17:12
11/13/19
11/13
17:12
11/13/19
17:12
Hot Stocks
FDA committee says benefits of empagliflozin do not outweigh risks »

The FDA Endocrinologic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

PRTH

Priority Technology

$3.24

-0.03 (-0.92%)

17:08
11/13/19
11/13
17:08
11/13/19
17:08
Earnings
Priority Technology reports Q3 EPS (9c), one estimate (12c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPZ

Domino's Pizza

$279.24

1.185 (0.43%)

17:07
11/13/19
11/13
17:07
11/13/19
17:07
Hot Stocks
Domino's Pizza's Goldman sells 2,486 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 11

    Dec

  • 12

    Dec

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

17:04
11/13/19
11/13
17:04
11/13/19
17:04
Periodicals
WeWork reported $1.25B loss in Q3, NY Times reports »

WeWork (WE) lost $1.25B…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLYC

GlycoMimetics

$6.27

0.31 (5.20%)

17:02
11/13/19
11/13
17:02
11/13/19
17:02
Initiation
GlycoMimetics initiated  »

GlycoMimetics resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$485.67

-1.24 (-0.25%)

17:00
11/13/19
11/13
17:00
11/13/19
17:00
Hot Stocks
BlackRock CFO sells nearly 4,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

ARVN

Arvinas

$28.35

1.85 (6.98%)

16:58
11/13/19
11/13
16:58
11/13/19
16:58
Initiation
Arvinas initiated  »

Arvinas initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FEYE

FireEye

$17.09

-0.04 (-0.23%)

16:57
11/13/19
11/13
16:57
11/13/19
16:57
Recommendations
FireEye analyst commentary  »

FireEye unique offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

CSCO

Cisco

$48.44

0.06 (0.12%)

16:54
11/13/19
11/13
16:54
11/13/19
16:54
Hot Stocks
Cisco says cyber security is a top priority for customers »

Says innovation pipeline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 09

    Dec

  • 10

    Dec

JPM

JPMorgan

$128.49

-0.65 (-0.50%)

16:54
11/13/19
11/13
16:54
11/13/19
16:54
Periodicals
JPMorgan's new HQ plan clears path for another NYC tower, Bloomberg says »

JPMorgan's plan to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 14

    Jan

SIBN

SI-Bone

$17.88

0.14 (0.79%)

16:53
11/13/19
11/13
16:53
11/13/19
16:53
Syndicate
Breaking Syndicate news story on SI-Bone »

SI-Bone files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLI

RLI Corp.

$97.43

0.78 (0.81%)

16:52
11/13/19
11/13
16:52
11/13/19
16:52
Hot Stocks
RLI Corp. declares special cash dividend of $1.00 per share »

Payable on December 20 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CPA

Copa Holdings

$107.71

1.89 (1.79%)

16:52
11/13/19
11/13
16:52
11/13/19
16:52
Hot Stocks
Copa Holdings reports Q3 load factor up 1.4pts to 85.6% »

Copa Holdings reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

XBIT

XBiotech

$11.42

0.18 (1.60%)

16:50
11/13/19
11/13
16:50
11/13/19
16:50
Recommendations
XBiotech analyst commentary  »

XBiotech price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AOBC

American Outdoor Brands

$7.90

0.22 (2.86%)

16:50
11/13/19
11/13
16:50
11/13/19
16:50
Hot Stocks
Breaking Hot Stocks news story on American Outdoor Brands »

American Outdoor Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPA

Copa Holdings

$107.71

1.89 (1.79%)

16:48
11/13/19
11/13
16:48
11/13/19
16:48
Earnings
Copa Holdings reports Q3 EPS $2.45, consensus $2.23 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

IDXG

Interpace Diagnostics

$0.78

0.0001 (0.01%)

, CGIX

Cancer Genetics

$2.93

-0.2 (-6.39%)

16:48
11/13/19
11/13
16:48
11/13/19
16:48
Hot Stocks
Interpace Diagnostics changes name to Interpace Biosciences »

Interpace Diagnostics…

IDXG

Interpace Diagnostics

$0.78

0.0001 (0.01%)

CGIX

Cancer Genetics

$2.93

-0.2 (-6.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 07

    Dec

TPTX

Turning Point Therapeutics

$48.68

0.84 (1.76%)

16:46
11/13/19
11/13
16:46
11/13/19
16:46
Initiation
Turning Point Therapeutics initiated  »

Turning Point…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBPO

China Biologic

$116.87

1.17 (1.01%)

16:46
11/13/19
11/13
16:46
11/13/19
16:46
Earnings
China Biologic raises FY19 income growth outlook to 11%-13% from 4%-6% »

The company is raising…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CBPO

China Biologic

$116.87

1.17 (1.01%)

16:45
11/13/19
11/13
16:45
11/13/19
16:45
Earnings
China Biologic reports Q3 adjusted EPS $1.40, one estimate 88c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

IDXG

Interpace Diagnostics

$0.78

0.0001 (0.01%)

16:45
11/13/19
11/13
16:45
11/13/19
16:45
Earnings
Breaking Earnings news story on Interpace Diagnostics »

Interpace Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

CSCO

Cisco

$48.44

0.06 (0.12%)

16:45
11/13/19
11/13
16:45
11/13/19
16:45
Hot Stocks
Breaking Hot Stocks news story on Cisco »

Cisco down about 5% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 09

    Dec

  • 10

    Dec

IDXG

Interpace Diagnostics

$0.78

0.0001 (0.01%)

16:44
11/13/19
11/13
16:44
11/13/19
16:44
Earnings
Interpace Diagnostics lowers 2019 revenue view to $28M-$32M from $33M-$36M »

Consensus for 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

IDXG

Interpace Diagnostics

$0.78

0.0001 (0.01%)

16:43
11/13/19
11/13
16:43
11/13/19
16:43
Earnings
Interpace Diagnostics reports Q3 EPS (19c), consensus (19c) »

Reports Q3 revenue $7.7M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.